trial

Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia

NCTId NCT00485901
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 50 (actual)
Sponsored by Eli Lilly and Company
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
50 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2004-07
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
OlanzapineHaloperidol

Sponsors

Eli Lilly and CompanyLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

1 total
Taipei, Taiwan

Facts & assertions

3 sourced
Enrollment
50
Phase
PHASE3
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
Haloperidol
drug
lead_sponsor
Eli Lilly and Company
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person